Momenta Phama (MNTA) Tops Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Momenta Pharmaceuticals (MNTA) PT Lowered to $26 at Stifel on 1Q Results; 'Patents & Production Issues Continue'
May 2, 2017 2:36 PM EDTStifel lowered its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $26.00 (from $30.00) while maintaining a Buy rating, as the company reported first quarter earnings results.
Analyst Thomas Shrader notes the company reported first quarter results, as management improved cash position due to a one-time... More
